Cogent Biosciences, Inc.
(NASDAQ : UMRX)

( )
UMRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.31%324.210.0%$4670.09m
BNTXBioNTech SE -1.06%247.680.0%$730.32m
NVAXNovavax, Inc. -4.59%161.9579.4%$715.24m
AMGNAmgen, Inc. 0.51%207.841.4%$575.65m
SNSSSunesis Pharmaceuticals, Inc. -7.57%6.470.7%$452.28m
GILDGilead Sciences, Inc. -0.76%67.631.0%$426.45m
REGNRegeneron Pharmaceuticals, Inc. -0.43%553.242.7%$408.99m
ILMNIllumina, Inc. 0.45%409.933.5%$392.87m
CCXIChemoCentryx, Inc. -7.04%34.472.9%$387.64m
XLRNAcceleron Pharma, Inc. 0.50%172.945.3%$345.45m
VRTXVertex Pharmaceuticals, Inc. -0.07%181.771.9%$259.59m
BIIBBiogen, Inc. -1.43%281.191.7%$243.39m
OCGNOcugen, Inc. -13.83%8.660.0%$178.37m
XENEXenon Pharmaceuticals, Inc. 2.12%33.660.4%$178.19m
JSPRJasper Therapeutics, Inc. 31.57%16.420.0%$158.53m

Company Profile

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.